Pfizer Adjusts Evaluation Score Amidst Mixed Financial Performance and Growth Challenges

Pfizer, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation score. This revision reflects a shift in technical trends, moving from a bullish stance to a mildly bullish outlook.
In terms of key financial metrics, Pfizer has demonstrated a high management efficiency, evidenced by a return on equity (ROE) of 18.22%. The company maintains a low debt-to-equity ratio, indicating a conservative approach to leverage. Recent quarterly results for Q1 FY25-26 have shown positive operating cash flow, reaching Rs 659.75 crore, alongside a notable dividend per share of Rs 165.00.

However, the company faces challenges in long-term growth, with net sales increasing at an annual rate of 1.81% and operating profit at 7.89% over the past five years. Despite a profit increase of 11.9% over the last year, the stock has generated a return of -6.63%. The current valuation appears elevated, with a price-to-book ratio of 5.9, suggesting that Pfizer is trading at a premium compared to its peers.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.